• Dexcom was selected as the first participant in the FDA’s TEMPO pilot program for digital health devices.
• The pilot will support an AI-driven glucose program tied to Dexcom G7 and Stelo, aimed at chronic disease management and real-world evidence generation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DexCom Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260722426337) on July 22, 2026, and is solely responsible for the information contained therein.